Dermatology

A recent study compared the annual cost per treated patient for a health plan for patients taking etanercept, adalimumab, or infliximab.

The National Psoriasis Foundation Medical Board released a statement supporting the prohibition of biosimilar substitution pending the fulfillment of 7 key measures.

An assessment of costs and specialty drug use within 4 chronic conditions found specialty drugs contribute to overall costs for insurance plan members.

In the first reported clinical study of topical tofacitinib, investigators concluded that the Janus kinase inhibitor effectively reduced the clinical signs of psoriasis.

The cost of complex therapies is soaring, and the challenge is to deliver access to these medications in the most cost-effective and clinically appropriate site of service.

Topical non-prescription products can provide relief from dermatitis.

A new study finds that patients with autoimmune diseases being treated with immunosuppressive drugs are not at an increased risk of developing shingles.

New efficacy and safety data from the Phase 3 PHOENIX 1 study, 1 of 2 pivotal registration trials, showed that maintenance treatment with Stelara (ustekinumab) for up to 5 years resulted in consistent, significant clinical response in adults with moderate to severe plaque psoriasis.

Patients with psoriasis need assistance balancing a complicated treatment plan can include phototherapy, topical medications, systemic agents, and biological treatments.